Meningitis B Outbreak in Kent: Strain Analysis and Vaccine Response
Health officials have completed an initial genetic analysis of the meningitis strain at the centre of the outbreak in Kent, providing crucial insights into the pathogen responsible for two deaths and nearly 30 cases. The UK Health Security Agency (UKHSA) has confirmed that the strain belongs to a group of bacteria known as group B meningococci, specifically sequence type 485 within the larger clonal complex ST-41/44.
Understanding the Strain
John Lees, group leader at the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI), explained that these genetic markers are low-resolution molecular fingerprints that offer limited information on their own. He noted, "What we do know is that this strain has probably been circulating since 2010 but increasing in frequency since then." Further analysis is ongoing to deepen understanding of the strain's characteristics and transmission patterns.
Is This a New Variant?
This strain is not a new variant, as it has been previously identified in the UK. However, experts suggest it appears to be a new subvariant. Brendan Wren, professor of microbial pathogenesis at the London School of Hygiene & Tropical Medicine (LSHTM), stated, "The menB ST-41/44 clonal complex has been previously identified in the UK, but the strain circulating in Kent appears to be a new subvariant." Similar strains have been circulating in the UK for approximately five years, but detailed analysis of the outbreak pathogen is still required, according to the UKHSA.
Vaccine Effectiveness
The current Bexsero menB vaccine is expected to provide protection against this strain, offering reassurance amid the outbreak. A vaccination programme in Kent is being rolled out to target high-risk groups, including anyone who attended Club Chemistry from March 5 to March 15, year 12 and 13 pupils at schools with cases, students and staff at the University of Kent and Canterbury Christ Church University, and close contacts of confirmed or suspected cases.
Case Numbers and Projections
As of Friday, March 20, the UKHSA reported that the number of cases linked to the outbreak in Kent has reached 29, up from 27. Of these, 18 cases have been confirmed, with a further 11 classified as probable cases. Among the confirmed cases, 13 are menB, and all cases have required hospital admission. Experts anticipate that the number of confirmed cases may rise, although there are indications that the peak has passed.
Paul Hunter, professor in medicine at the University of East Anglia, commented, "The incubation period though a little uncertain ranges from two to 10 days, so I think we can be fairly certain that the peak from the initial superspreading event will have already passed." However, he warned that secondary cases—where individuals did not get infected at the nightclub but from someone else who was there—remain a possibility.
Public Health Response
Dr. Michael Head, senior research fellow in global health at the University of Southampton, added, "Given the extent of contact tracing from public health teams, and the widespread publicity, it is plausible that we are seeing the tail-end of this outbreak." In terms of intervention measures, as of 5pm on Thursday, March 19, 2,360 vaccinations had been administered, and 9,840 doses of antibiotics had been prescribed. Additional vaccination centres have been opened to enhance access and containment efforts.
